|
A Phase II Clinical Trial of ABI-007, Administered Weekly in Taxol Resistant Patients with Metastatic Breast Cancer Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about A Phase II Clinical Trial of ABI-007, Administered Weekly in Taxol Resistant Patients with Metastatic Breast Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Phase II Clinical Trial of ABI-007, Administered Weekly in Taxol Resistant Patients with Metastatic Breast Cancer Clinical research trials and A Phase II Clinical Trial of ABI-007, Administered Weekly in Taxol Resistant Patients with Metastatic Breast Cancer health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like A Phase II Clinical Trial of ABI-007, Administered Weekly in Taxol Resistant Patients with Metastatic Breast Cancer. A Phase II Clinical Trial of ABI-007, Administered Weekly in Taxol Resistant Patients with Metastatic Breast Cancer Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a A Phase II Clinical Trial of ABI-007, Administered Weekly in Taxol Resistant Patients with Metastatic Breast Cancer clinical trial. Subjects frequently get the best healthcare possible for their A Phase II Clinical Trial of ABI-007, Administered Weekly in Taxol Resistant Patients with Metastatic Breast Cancer condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase II Clinical Trial of ABI-007, Administered Weekly in Taxol Resistant Patients with Metastatic Breast Cancer  A Phase II Clinical Trial of ABI-007, Administered Weekly in Taxol Resistant Patients with Metastatic Breast Cancer
A Phase II Clinical Trial of ABI-007, Administered Weekly in Taxol Resistant Patients with Metastatic Breast Cancer
For Condition: Breast Neoplasms,Metastases, Neoplasm
Status: Recruiting
Sponsor(s): American Bioscience ,
Synopsis: The anticancer agent paclitaxel (marketed as Taxol) has shown remarkable activity against metastatic breast cancer. However, the Taxol formulation requires prolonged administration times, and there are safety problems that have been attributed to the solvent rather than the active ingredient, paclitaxel. This is a new formulation of paclitaxel that has been found to have fewer safety problems than Taxol, and may be administered safely at higher doses. This study will investigate the safety and efficacy of this new formulation of paclitaxel given intravenously once a week for three weeks, followed by a rest week. This cycle will be repeated until safety problems or treatment failure require that the patient stop therapy.
Details: The anticancer agent paclitaxel (Taxol for Injection Concentrate, Bristol-Meyers Squibb) has a broad spectrum of activity against several human cancers including carcinomas of ovary, breast, lung, esophagus and head and neck cancer. Taxol has shown remarkable activity against metastatic breast cancer, yielding response rates in the range of 40% to 60% in chemotherapy-naive patients and 25%-30% in patients refractory to anthracycline-containing regimens (Taxol package insert). The major limitation of Taxol is its poor water soluability requiring Cremophor (containing castor oil and ethanol) as a solvent. Taxol in this vehicle must be administered over 3-24 hours, and hypersensitivity reactions to Cremophor require a premedication routine of a corticosteroid, an antihistamine, and an H2 antagonist. In this study, the test medication (ABI-007) is a nanoparticle colloidal composition of protein-stabilized paclitaxel that is reconstituted in saline. The infusion time for ABI-007 is minimal compared to Taxol (under an hour), and there is no premedication required. The maximally tolerated dose of this formulation of paclitaxel is 300 mg/m2, as compared to 175 mg/m2 for Taxol. As tumor response has been shown to be dose-dependent for paclitaxel, a higher dose allows for a potentially better response. This open-label, Phase II study will determine the safety, tolerability and anti-tumor effect of ABI-007 monotherapy administered weekly in patients with metastatic breast cancer that have been previously treated with Taxol.
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Patients must be: - If female, non-pregnant and not lactating, with a negative serum pregnancy test, and either not of child-bearing potential or practicing an approved contraception method - Eighteen years of age or older - Karnofsky Perfomance Status of 70% or 0-2 SWOG Performance Status - No other malignancy, except non-melanoma skin cancer, CIN, or in-situ cervical cancer - Measurable disease - Suitable candidate for treatment with paclitaxel - Previously treated with Taxol weekly or every three weeks, including adjuvant therapy, for metastatic breast cancer and relapsed within 12 months - If, at baseline, patient has absolute neutrophil count of at least 1500 cells/mm3, platelet count of at least 100,000 cells/mm3,and hemoglobin of at least 9 g/dL - If, at baseline, patient has AST and ALT of less than or equal to 2.5 x the upper limit of normal range; a total bilirubin less than or equal to 1.5 mg/dL; creatinine levels less than or equal to 2 mg/dL; and alkaline phosphatase levels less than or equal to 5 x the upper limit of normal range (unless there are bone but not liver metastases) - Patient has an expected survival of at least 12 weeks - Patient or his/her representative has signed an informed consent statement
Total Enrollment: 100
Location and Contact Information:
Overall Study Official:
MichaelHawkins, Study Director, American Bioscience, Inc.
American Bioscience, Inc. *Recruiting*
Raleigh, North Carolina, 27609
United States
Recruiting Jean Lewis 919-789-9141
Additional Information:
Study ID Numbers: CA013-0;
Study Start Date: June 2001
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00046514
Other Metastases, Neoplasm Studies:
1. An investigational drug (CAL) versus zoledronic acid (Zometa®) in patients with breast cancer
2. Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer
3. Use of Dynamic Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor-Associated Vasculature in Patients with Metastatic Breast Cancer
4. Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast Cancer
5. Inflammatory Breast Cancer and Tumor Markers
Related Studies:
Other Metastases, Neoplasm Clinical Trials
Other North Carolina Clinical Trials
Other Raleigh Clinical Trials
A Phase II Clinical Trial of ABI-007, Administered Weekly in Taxol Resistant Patients with Metastatic Breast Cancer
|
|
|
|
|
|
|
|
